Merrimack Pharmaceuticals

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Even with a new earnings season underway, insiders were still making notable share purchases. Some of those insiders made return trips to the buy window, and a couple of chief...

Shares of Merrimack Pharmaceuticals Inc (NASDAQ: MACK) fell more than 20 percent early Wednesday morning after the company announced that it will stop a Phase 2 study of its treatment to fight breast cancer. The Phase 2 study was called HERMIONE and evaluated its only drug MM-302, an antibody-...

Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...

U.S. stocks were little moved to start off the month of May as investors and traders are cautious before April's nonfarm payrolls report are released on Friday. The consensus estimate for Friday's figure stands at 215,000 which would trump March's 192,000 number. “This is a really important...

Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma (NASDAQ: GEVA). Ariad Pharmaceuticals Shares of this...